Five articles suggested by Yüksel Ürün
Yüksel Ürün is a Medical Oncology professor at Ankara University School of Medicine in Turkey. His research focuses on genitourinary cancers, covering epidemiology, diagnosis, biomarkers, meta-analysis, and treatment outcomes. His dedication to patient care and research inspires positive change in the medical field.
He suggested following few must-read papers on X:
1.”Bladder preservation in MIBC?
A novel approach with dual checkpoint blockade (durvalumab+tremelimumab) + radiotherapy shows 81% complete response & 65% 2-yr bladder-intact DFS.
Promising alternative to cystectomy?”
Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial.
Authors: Xavier Garcia-del-Muro, et al.
2.”CAR-T & Second Primary Cancers (SPCs).
CAR-T therapy is practice-changing in hematologic cancers, but concerns about SPCs are rising.
Data suggest SPCs are rare (≈4%), with transgene-positive cases even rarer.
CAR-T remains a powerful tool, but vigilance is key.”
Second Primary Cancer After Chimeric Antigen Receptor–T-Cell Therapy: A Review.
Authors: Shyam A. Patel, et al.
3.”Can biopsy be omitted after a negative MRI in suspected prostate cancer?
In a 3-year study of 593 men, 48% had negative MRI results—86% avoided biopsy.
Only 4% of those monitored developed clinically significant prostate cancer.
MRI has high negative predictive value, making biopsy omission safe with proper monitoring!”
Oncological Safety of MRI-Informed Biopsy Decision-Making in Men With Suspected Prostate Cancer.
Authors: Charlie A. Hamm, et al.
4.”Physical inactivity contributes to 13 types of cancer—not just colon, endometrial, and breast cancer.
In 2015, 30,951 cases in the U.S. could have been prevented with more movement.
Time to act!”
Estimating cancer incidence attributable to physical inactivity in the United States.
Authors: Brigid M. Lynch, et al.
5.”A new mRNA cancer vaccine shows promise in pancreatic cancer!
In a small study, patients whose immune systems responded to the vaccine had a much lower chance of cancer coming back (RFS not reached vs. 13.4 months; p=0.007).
The vaccine created long-lasting T cells that stayed active for years.
Could this be a breakthrough for cancer vaccines?”
RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer.
Authors: Zachary Sethna, et al.
More posts featuring Yüksel Ürün.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023